JP2022500381A5 - - Google Patents

Info

Publication number
JP2022500381A5
JP2022500381A5 JP2021513254A JP2021513254A JP2022500381A5 JP 2022500381 A5 JP2022500381 A5 JP 2022500381A5 JP 2021513254 A JP2021513254 A JP 2021513254A JP 2021513254 A JP2021513254 A JP 2021513254A JP 2022500381 A5 JP2022500381 A5 JP 2022500381A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
alkyl
optionally substituted
kras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021513254A
Other languages
English (en)
Japanese (ja)
Other versions
JP7546549B2 (ja
JP2022500381A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/050224 external-priority patent/WO2020055755A1/en
Publication of JP2022500381A publication Critical patent/JP2022500381A/ja
Publication of JP2022500381A5 publication Critical patent/JP2022500381A5/ja
Priority to JP2024091743A priority Critical patent/JP2024133475A/ja
Application granted granted Critical
Publication of JP7546549B2 publication Critical patent/JP7546549B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513254A 2018-09-10 2019-09-09 組み合わせ療法 Active JP7546549B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024091743A JP2024133475A (ja) 2018-09-10 2024-06-05 組み合わせ療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729169P 2018-09-10 2018-09-10
US62/729,169 2018-09-10
PCT/US2019/050224 WO2020055755A1 (en) 2018-09-10 2019-09-09 Combination therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024091743A Division JP2024133475A (ja) 2018-09-10 2024-06-05 組み合わせ療法

Publications (3)

Publication Number Publication Date
JP2022500381A JP2022500381A (ja) 2022-01-04
JP2022500381A5 true JP2022500381A5 (cg-RX-API-DMAC7.html) 2022-09-16
JP7546549B2 JP7546549B2 (ja) 2024-09-06

Family

ID=69776771

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021513254A Active JP7546549B2 (ja) 2018-09-10 2019-09-09 組み合わせ療法
JP2024091743A Pending JP2024133475A (ja) 2018-09-10 2024-06-05 組み合わせ療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024091743A Pending JP2024133475A (ja) 2018-09-10 2024-06-05 組み合わせ療法

Country Status (14)

Country Link
US (2) US20220040181A1 (cg-RX-API-DMAC7.html)
EP (2) EP4552631A3 (cg-RX-API-DMAC7.html)
JP (2) JP7546549B2 (cg-RX-API-DMAC7.html)
DK (1) DK3849534T3 (cg-RX-API-DMAC7.html)
ES (1) ES3017461T3 (cg-RX-API-DMAC7.html)
FI (1) FI3849534T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250480T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071715T2 (cg-RX-API-DMAC7.html)
LT (1) LT3849534T (cg-RX-API-DMAC7.html)
PL (1) PL3849534T3 (cg-RX-API-DMAC7.html)
PT (1) PT3849534T (cg-RX-API-DMAC7.html)
RS (1) RS66727B1 (cg-RX-API-DMAC7.html)
SI (1) SI3849534T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020055755A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3112043A1 (en) * 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) * 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
CN114616232B (zh) * 2019-09-06 2026-05-05 正大天晴药业集团南京顺欣制药有限公司 氮杂环庚烷并嘧啶类衍生物及其医药用途
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
BR112022006394A2 (pt) 2019-10-02 2022-07-26 Tolremo Therapeutics Ag Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer
US20230257374A1 (en) * 2019-10-10 2023-08-17 Innovent Biologics (Suzhou) Co., Ltd. Novel kras g12c protein inhibitor, preparation method therefor, and use thereof
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
WO2021108682A1 (en) 2019-11-27 2021-06-03 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
TW202144349A (zh) * 2020-04-30 2021-12-01 大陸商上海科州藥物研發有限公司 作為kras抑制劑的雜環化合物的製備及其應用方法
WO2021231526A1 (en) * 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
CN113683616B (zh) * 2020-05-18 2025-12-30 广州百霆医药科技有限公司 Kras g12c突变蛋白抑制剂
WO2021260110A1 (en) 2020-06-25 2021-12-30 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
AU2021298154A1 (en) * 2020-06-25 2023-02-23 Tolremo Therapeutics Ag Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
CA3212085C (en) 2021-04-07 2025-02-11 Tolremo Therapeutics Ag HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR RELIEF OF CANCER
CN113429405A (zh) * 2021-06-10 2021-09-24 都创(上海)医药开发有限公司 Mrtx849化合物的晶型及其制备方法和用途
CN117940132A (zh) * 2021-06-24 2024-04-26 医睿世康药业研发公司 Erk1/2和kras g12c抑制剂组合疗法
WO2023283213A1 (en) 2021-07-07 2023-01-12 Incyte Corporation Tricyclic compounds as inhibitors of kras
CA3224841A1 (en) 2021-07-14 2023-01-19 Zhenwu Li Tricyclic compounds as inhibitors of kras
CA3229855A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
KR20240114793A (ko) 2021-11-05 2024-07-24 프론티어 메디슨즈 코포레이션 Kras g12c 억제제
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
CN119607214B (zh) * 2025-02-17 2025-06-20 四川大学华西医院 Src抑制剂联合kras-g12c抑制剂用于制备治疗kras-g12c突变型肺癌的药物中的应用及药物组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2452603A1 (en) 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
US20040014676A1 (en) 2001-07-09 2004-01-22 Ramalinga Dharanipragada SRC kinase inhibitors useful for treating osteoporosis
EP2258371A1 (en) 2001-08-10 2010-12-08 Novartis AG Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
US8283441B2 (en) 2006-10-31 2012-10-09 University Of Toledo Na+K+-ATPase-specific peptide inhibitors/activators of SRC and SRC family kinases
CN101677979A (zh) 2007-04-19 2010-03-24 利奥制药有限公司 Src家族激酶抑制剂
CN104230901A (zh) 2008-09-15 2014-12-24 加利福尼亚大学董事会 用于调节ire1、src和abl活性的方法和组合物
US9090617B1 (en) 2011-08-03 2015-07-28 National Taiwan University Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
PL2739139T3 (pl) 2011-08-03 2020-06-15 National Taiwan University Agoniści białkowej fosfatazy tyrozynowej 1 zawierającej domeny homologii z src 2 i sposoby leczenia z ich zastosowaniem
CA2944198C (en) 2013-04-26 2021-11-16 Indiana University Research & Technology Corporation Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US9862701B2 (en) * 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
ES2863873T3 (es) * 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
JP7327802B2 (ja) * 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
CA3082579A1 (en) 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors

Similar Documents

Publication Publication Date Title
JP2022500388A5 (cg-RX-API-DMAC7.html)
JP2022500385A5 (cg-RX-API-DMAC7.html)
JP2022500384A5 (cg-RX-API-DMAC7.html)
JP2022509724A5 (cg-RX-API-DMAC7.html)
JP2022500379A5 (cg-RX-API-DMAC7.html)
JP7357135B2 (ja) ピリダジノン化合物およびその使用
HRP20230377T1 (hr) Inhibitori mutacije kras g12c
JP2019516718A5 (cg-RX-API-DMAC7.html)
JP2025506408A5 (cg-RX-API-DMAC7.html)
IL314486A (en) Quinazoline compounds inhibit PAN-KRAS
CN113272291B (zh) 哒嗪酮化合物及其用途
JP2025000630A5 (cg-RX-API-DMAC7.html)
JP2025000632A5 (cg-RX-API-DMAC7.html)
JP2024133475A (ja) 組み合わせ療法
JP2024537140A5 (cg-RX-API-DMAC7.html)
EP2925744B1 (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
JP2022548255A5 (cg-RX-API-DMAC7.html)
JP2025000629A5 (cg-RX-API-DMAC7.html)
JP2024537136A5 (cg-RX-API-DMAC7.html)
JP2022548791A5 (cg-RX-API-DMAC7.html)
HRP20250059T1 (hr) Kombinirane terapije
AU2010222122B2 (en) Piperazine compound capable of inhibiting prostaglandin D synthase
BR112020015583A2 (pt) composto, composição farmacêutica, e, métodos para inibir a atividade de prc2 em uma célula e para tratar câncer
EP2582432A1 (en) Ureido-pyrazole derivatives for use in the treatment of respiratory syncitial virus (rsv) infection
BRPI0806245B1 (pt) Compostos de fórmula i e seus usos